- The global cancer therapy market will increase from $40.0 billion in 2007 to an estimated $47.3 billion by the end of 2008. It should reach $110.6 billion in 2013, a compound annual growth rate (CAGR) of 18.5%.
- Breast cancer therapy is the largest market with about $11.0 billion in sales in 2007. This is expected to increase to $12.0 billion by the end of 2008 and $26.5 billion in 2013, for a CAGR of 16.4%.
- Target therapy dominated in 2007 with a 45% share of the total cancer therapy market. This is expected to increase to 48% by the end of 2008 and 62.5% in 2013.
BCC’s goal in conducting this study is to provide an overview of the current and potential aspects of the global market for cancer therapies. The report determines the market size, market leaders, and factors affecting the market for cancer therapies with the inclusion of the market by disease sector.
The overview of types of diseases and different therapies in cancer is also examined along with sale figures over the 5-year period from 2008 to 2013. Companies manufacturing/selling the drugs to treat cancer are profiled, and the factors affecting markets for these products and how those markets are likely to change are analyzed. Revenues have been broken down by the type of therapies and by different regions.
Our key objective is to present a comprehensive analysis of the current and future market and to analyze the future direction of cancer therapies with an emphasis on newer products.
REASONS FOR DOING THIS STUDY
Due to continuous technology advances in research and development in the field of oncology and the requirement for newer and more effective pharmaceutical drugs/therapies, companies are investing in the development of these new products to lessen the side effects and target the disease. A fundamental change in cancer therapies is underway with a shift from the use of chemotherapy drugs to targeted therapy or the use of chemotherapy drugs along with targeted therapies. Targeted therapies are being developed for targeting cancer cells more specifically. Targeted therapies are more efficacious and less toxic than chemotherapy due to their more selective nature.
This study looks at almost all types of therapies/products used in oncology. The study conducts the prevalence of cancer globally. The research and development of new products and major changes in market behavior justify focusing on this segment. Finally, this study discusses the usage of these drug therapies by disease sector to determine the usage in each sector.
CONTRIBUTIONS OF THE STUDY AND FOR WHOM
The study contributes to the areas of market growth and decline in cancer therapies from the point of view of manufacturers and users. This study will be of interest largely to the pharmaceutical and biopharmaceutical industries, clinics, and hospitals.
SCOPE OF THE STUDY
The scope of this study encompasses the markets for cancer therapies. BCC analyzes each market and its market leaders; different types of therapies; the prevalence of cancer; the regulatory environment; the different disease sectors for cancer; and market projections and market share. Technological issues include the latest trends and new developments
Both primary and secondary sources were used for this research. A comprehensive literature search was conducted. The literature included technical newsletters and journals as well as many other sources. The data were collected through interviews and correspondence with various pharmaceutical/biotechnical experts. Projections were based on estimates such as the current number of end users, potential end users, likely unit prices, rates of consumption, and market trends.
BCC surveyed many companies to obtain data for this study. Included were manufacturers and end users of cancer drugs. We gathered the data; spoke with officials of this industry; and reviewed newsletters, company literature, product literature, a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases by key terminology were done. In addition, we compiled data from current financial and trade information and government sources.
ABOUT THE AUTHOR
Shalini Shahani Dewan holds a Masters degree in Pharmaceutical Chemistry. Among the research topics she has covered are studies on compounds of potential pharmaceutical interest from ibuprofen and 2-naphthyl acetic acid. Shahani was awarded a gold medal by the prime minister of India for her work and has worked with top companies in India and in the U.S. Some of her other reports with BCC are “Reagents of Chromatography;” “Spectroscopy, an Enduring Market;” “Advanced Drug Delivery Systems;” “Orthopedic Drugs, Implants, and Devices;” “Imaging Reagents;” “Contract Manufacturing, Research and Packaging;” “The Dynamic Media, Sera, and Reagent market in Biotechnology;” “Opportunities in Chiral Technology;” “Behavioral and Emotional Disorders in Children and Adolescents;” and “Pharmaceutical Regulatory Industry”.
The total worldwide cancer drug market approached $14.8 billion in 2000.
Growing at an average annual rate (AAGR) of 12.5%, this market is expected to exceed $26.7 billion in 2005.
Established product lines currently constitute nearly 90% of the market, but will grow at only a 6.6% AAGR through the period.
Innovative therapies, climbing at an AAGR of 40.2%, will reach $8.6 billion in 2005, representing 32% of the total market.